Chapter Eight - A comparative computational approach toward pharmacological chaperones (NN-DNJ and Ambroxol (cas 18683-91-5)) on N370S and L444P mutations causing Gaucher's disease
-
Add time:09/27/2019 Source:sciencedirect.com
Gaucher's disease (GD) is the most commonly known lysosomal disorder that occurs due to mutations in the β-glucocerebrosidase (GBA) protein. Our previous findings (Thirumal Kumar, Eldous, Mahgoub, George Priya Doss, Zayed, 2018) and other reports concluded that the mutations N370S and L444P are the most significant mutations that could cause disruptions in protein stability and structure. These disruptions lead to protein misfolding and result in a diseased condition. Enzyme Replacement Therapy (ERT) and Pharmacological chaperone therapy (PCT) are currently used to treat GD caused by mutations in the GBA protein. The extreme disparity in cost between ERT and chaperone therapy, shifted the attention toward chaperone therapy. The most common chaperones in the market and trial phases to treat GD are Isofagomine, Miglustat, Eliglustat, NN-DNJ, and Ambroxol. In the era of personalized medicine, it is often necessary to understand the drug likeliness of each chaperone. In this context, the present study utilized molecular docking analysis to understand the interaction behavior of the chaperone toward the native and the two mutants N370S and L444P. The molecular dynamics simulation analyses performed on chaperones (NN-DNJ and Ambroxol) interaction showed that the chaperone NN-DNJ possesses better affinity toward the protein with N370S mutation whereas chaperone Ambroxol showed better activity against both the significant mutations (N370S and L444P). This study is expected to serve as a platform for drug repurposing.
We also recommend Trading Suppliers and Manufacturers of Ambroxol (cas 18683-91-5). Pls Click Website Link as below: cas 18683-91-5 suppliers
Prev:Time-shifted co-administration of sub-analgesic doses of Ambroxol (cas 18683-91-5) and pregabalin attenuates oxaliplatin-induced cold allodynia in mice
Next:Inhalation of Ambroxol (cas 18683-91-5) inhibits cigarette smoke-induced acute lung injury in a mouse model by inhibiting the Erk pathway) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Ambroxol (cas 18683-91-5) as a pharmacological chaperone for mutant glucocerebrosidase09/30/2019
- Original articleThe chaperone activity and toxicity of Ambroxol (cas 18683-91-5) on Gaucher cells and normal mice09/29/2019
- Original ArticleCiprofloxacin plus erythromycin or Ambroxol (cas 18683-91-5) ameliorates endotracheal tube-associated Pseudomonas aeruginosa biofilms in a rat model09/28/2019
- Inhalation of Ambroxol (cas 18683-91-5) inhibits cigarette smoke-induced acute lung injury in a mouse model by inhibiting the Erk pathway10/01/2019
- Time-shifted co-administration of sub-analgesic doses of Ambroxol (cas 18683-91-5) and pregabalin attenuates oxaliplatin-induced cold allodynia in mice09/26/2019
- In vitro pharmacology of Ambroxol (cas 18683-91-5): Potential serotonergic sites of action09/25/2019
- Short CommunicationEffect of Ambroxol (cas 18683-91-5) chaperone therapy on Glucosylsphingosine (Lyso-Gb1) levels in two Canadian patients with type 3 Gaucher disease09/24/2019
- Protective effects of Ambroxol (cas 18683-91-5) in psoriasis like skin inflammation: Exploration of possible mechanisms09/10/2019
-
Health and Chemical more >
-
Related Products


